Solid Biosciences Inc. (SLDB) News
Follow Solid Biosciences Inc. (SLDB) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 13 public stories across 9 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Solid Biosciences Reports Third-Quarter 2026 Financial Results
Solid Biosciences reported third-quarter 2026 financial results. The supplied body says SGT-003 has been generally well tolerated in 53 participants dosed.
EQUITY | Nov 04, 2026, 09:15 PM UTC
M
Solid Biosciences Q3'26 Earnings Preview
Solid Biosciences is scheduled to report Q3'26 results on November 11.
EQUITY | Nov 04, 2026, 12:01 PM UTC
L
SLDB: Advancing novel gene therapies for DMD and FA, with pivotal FDA meetings and data ahead
The company is advancing AAV gene therapies for DMD and FA, prioritizing these programs with novel constructs and delivery platforms. Key FDA meetings and data readouts are expected in the next two quarters, with a stron
REGULATION | Sep 14, 2026, 07:57 PM UTC
L
SLDB: Advancing gene therapies for DMD and FA with novel delivery, key FDA meetings, and strong cash runway
The company is advancing gene therapies for Duchenne muscular dystrophy and Friedreich's ataxia, with key FDA meetings and data readouts expected in the next two quarters. Novel delivery platforms and simplified immunosu
REGULATION | Sep 14, 2026, 07:28 PM UTC
L
SLDB says FDA will review one-year DMD data in Q4
SLDB expects key regulatory meetings and data releases for DMD and FA over the next six months. It says the FDA will review one-year data from over 12 DMD patients and initial mFARS data from FA patients due in Q1.
REGULATION | Sep 10, 2026, 09:09 PM UTC
L
SLDB: Advancing gene therapies for DMD and FA with novel delivery platforms and global ambitions
Gene therapy programs for DMD and FA are advancing, with high demand and robust biomarker strategies supporting clinical development. Novel capsid technology enables superior biodistribution and safety, while streamlined
EQUITY | Sep 09, 2026, 09:23 PM UTC
L
Solid Biosciences to participate in upcoming investor conferences
Solid Biosciences Inc. (SLDB) said it will participate in upcoming investor conferences, as announced in a company update.
EQUITY | Sep 02, 2026, 12:07 PM UTC
L
SLDB - Solid Biosciences to Participate at Upcoming Investor Conferences
SLDB - Solid Biosciences to Participate at Upcoming Investor Conferences
EQUITY | Sep 02, 2026, 12:00 PM UTC
L
Cantor Fitzgerald raises Solid Biosciences PT to $26 from $16
Cantor Fitzgerald raised its price target on Solid Biosciences to $26.00 per share from $16.00.
EQUITY | Aug 27, 2026, 10:45 AM UTC
M
SLDB: Truist assumes Buy; raises PT to $20 from $16
Hammerstone MarketTalk says Truist initiates/assumes coverage at Buy and raises its price target for SLDB to $20 from $16.
EQUITY | Aug 21, 2026, 12:32 PM UTC
L
SLDB: Truist Securities initiates Buy with $20.00 price target
Truist Securities initiates coverage on SLDB with a Buy rating and a $20.00 price target, according to Hammerstone MarketTalk.
EQUITY | Aug 21, 2026, 11:58 AM UTC
H
Airsculpt Technologies, Barrick Mining And Other Big Stocks Moving Lower In Monday’s Pre-Market Session
U.S. stock futures were mixed this morning, with the Dow futures falling around 0.1% on Monday. Shares of Airsculpt Technologies Inc (NASDAQ: AIRS ) fell sharply in pre-market trading following second-quarter results. Ai
EARNINGS | Aug 10, 2026, 12:02 PM UTC
L
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Curis (NASDAQ: CRIS ) stock rose 9.0% to $0.46 during Wednesday's after-market session. The company's market cap stands at $20.3 million. Humacyte (NASDAQ: HUMA ) shares moved upwards by 5.45% to $0.71. The marke
EQUITY | Jul 01, 2026, 09:05 PM UTC